Aztreonam: clinical and pharmacological characteristics at the present stage

One of the urgent problems of modern health care is the growing resistance of microorganisms to antibiotics, including carbapenems, which until recently were considered as the drugs of choice in the treatment of life-threatening infections. Enzymatic inactivation of antibiotics, including through the production of carbapenemase, is the main mechanism of resistance in Gram-negative bacteria. The treatment of these infections presents significant difficulties due to the extremely limited arsenal of effective drugs. Aztreonam is currently the first and only monocyclic beta-lactam antibiotic, monobactam, which is used in clinical practice for the treatment of infections caused by gram-negative bacteria. The data obtained in vitro and clinical observations are presented. These results justify the use of the drug in infections caused by a number of «problem» Gram-negative pathogens, including those resistant to carbapenems. Aztreonam has a high potential and should be used to treat patients with nosocomial infections – the focus of its use is Gram-negative bacteria-producers of metallo-beta-lactamases.

[1]  M. Biswal,et al.  In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era , 2022, The Journal of Antibiotics.

[2]  J. Timsit,et al.  Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients , 2022, Antibiotics.

[3]  S. Di Bella,et al.  Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections , 2021, Antibiotics.

[4]  S. Aka,et al.  Prevalence and characterisation of carbapenemase encoding genes in multidrug-resistant Gram-negative bacilli , 2021, PloS one.

[5]  S. Di Bella,et al.  The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases , 2021, Antibiotics.

[6]  Jongyoun Yi,et al.  Identification and infection control of carbapenem-resistant Enterobacterales in intensive care units , 2021, Acute and critical care.

[7]  Y. Akeda.  Current situation of carbapenem‐resistant Enterobacteriaceae and Acinetobacter in Japan and Southeast Asia , 2021, Microbiology and immunology.

[8]  D. Nicolau,et al.  Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing Enterobacterales in Animal Infection Models: a Current State of Affairs , 2021, Antimicrobial Agents and Chemotherapy.

[9]  Anna E. Kasimati,et al.  Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae , 2021, European Journal of Clinical Microbiology & Infectious Diseases.

[10]  M. Edelstein,et al.  AMRmap – antibiotic resistance surveillance system in Russia , 2021, Clinical Microbiology and Antimicrobial Chemotherapy.

[11]  F. Forfori,et al.  Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Castanheira,et al.  Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide , 2020, Antimicrobial Agents and Chemotherapy.

[13]  M. Zeitlinger,et al.  Compatibility of aztreonam in four commercial peritoneal dialysis fluids , 2020, Scientific Reports.

[14]  Y. Doi,et al.  Aztreonam Combination Therapy: A Long-Awaited Answer to Metallo-β-Lactamase-Producing Gram-Negatives? , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Zampino,et al.  Management of carbapenem-resistant Enterobacteriaceae infections. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  T. Naas,et al.  Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria , 2019, Antimicrobial Agents and Chemotherapy.

[17]  Asad U. Khan,et al.  Combination of aztreonam and cefotaxime against CTX-M-15 type β-lactamases: A mechanism based effective therapeutic approach. , 2018, International journal of biological macromolecules.

[18]  P. Nordmann,et al.  Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae , 2018, The Journal of antimicrobial chemotherapy.

[19]  M. Rottman,et al.  Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa , 2017, Antimicrobial Agents and Chemotherapy.

[20]  Diansong Zhou,et al.  Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis , 2017, Journal of clinical pharmacology.

[21]  C. Ramsey,et al.  A review of the pharmacokinetics and pharmacodynamics of aztreonam. , 2016, The Journal of antimicrobial chemotherapy.

[22]  K. Bush.  A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. , 2015, International journal of antimicrobial agents.

[23]  A. Friggeri,et al.  Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study. , 2015, Anaesthesia, critical care & pain medicine.

[24]  J. Wingard,et al.  Aztreonam for febrile neutropenia in patients with beta‐lactam allergy , 2014, Transplant infectious disease : an official journal of the Transplantation Society.

[25]  J. Brooke.  Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen , 2012, Clinical Microbiology Reviews.

[26]  R. Bonomo,et al.  Exploring sequence requirements for C3/C4 carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β‐lactamase , 2011, Protein science : a publication of the Protein Society.

[27]  A. Buonomo,et al.  Tolerability of Aztreonam in Patients with Cell-Mediated Allergy to β-Lactams , 2010, International Archives of Allergy and Immunology.

[28]  N. Woodford,et al.  Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae , 2010, Antimicrobial Agents and Chemotherapy.

[29]  A. Buonomo,et al.  Tolerability of Aztreonam in Patients with IgE-Mediated Hypersensitivity to Beta-Lactams , 2008, International journal of immunopathology and pharmacology.

[30]  K. Bush,et al.  Carbapenemases: the Versatile β-Lactamases , 2007, Clinical Microbiology Reviews.

[31]  Ronald N. Jones,et al.  Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli. , 2003, Diagnostic microbiology and infectious disease.

[32]  Jerome J. Schentag,et al.  Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. , 2001, Clinical therapeutics.

[33]  C. Sanders,et al.  Cefepime-Aztreonam: a Unique Double β-Lactam Combination for Pseudomonas aeruginosa , 1998, Antimicrobial Agents and Chemotherapy.

[34]  R. Sykes,et al.  Discovery and development of the monobactams. , 1985, Reviews of infectious diseases.

[35]  S. Norrby.  Clinical experience with aztreonam in Europe: a summary of studies in Belgium, England, Finland, Ireland, the Netherlands, Norway, Portugal, and Sweden. , 1985, Reviews of infectious diseases.

[36]  R. Sykes,et al.  Aztreonam: the first monobactam. , 1985, The American journal of medicine.

[37]  J. S. Wells,et al.  Monocyclic β-lactam antibiotics produced by bacteria , 1981, Nature.

[38]  M. Muroi,et al.  Sulfazecin and isosulfazecin, novel β-lactam antibiotics of bacterial origin , 1981, Nature.

[39]  R. Ambler,et al.  The structure of beta-lactamases. , 1980, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.